NO329209B1 - Farmasoytisk preparat inneholdende et sulfopyranosylacylglyserolderivat, slike forbindelser for anvendelse ved behandling av kreft, samt anvendelse av forbindelsene ved fremstilling av medikamenter - Google Patents

Farmasoytisk preparat inneholdende et sulfopyranosylacylglyserolderivat, slike forbindelser for anvendelse ved behandling av kreft, samt anvendelse av forbindelsene ved fremstilling av medikamenter Download PDF

Info

Publication number: NO329209B1
Authority: NO; Norway
Prior art keywords: group; compound; reaction; compounds; fatty acid
Prior art date: 1999-02-26

Application number

NO20014119A

Other languages

English (en)

Norwegian (no)

Other versions

NO20014119L (no

NO20014119D0 (no

Inventor

Takayuki Yamazaki

Fumio Sugawara

Keisuke Ohta

Kazuyoshi Masaki

Kotaro Nakayama

Kengo Sakaguchi

Noriyuki Sato

Hiroeki Sahara

Tatsuya Fujita

Original Assignee

Toyo Suisan Kaisha

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-02-26

Filing date

2001-08-24

Publication date

2010-09-13

2001-08-24 Application filed by Toyo Suisan Kaisha filed Critical Toyo Suisan Kaisha

2001-08-24 Publication of NO20014119D0 publication Critical patent/NO20014119D0/no

2001-10-24 Publication of NO20014119L publication Critical patent/NO20014119L/no

2010-09-13 Publication of NO329209B1 publication Critical patent/NO329209B1/no

Links

150000001875 compounds Chemical class 0.000 title claims abstract description 93
239000003814 drug Substances 0.000 title claims abstract description 18
206010028980 Neoplasm Diseases 0.000 title claims description 28
201000011510 cancer Diseases 0.000 title claims description 14
239000000825 pharmaceutical preparation Substances 0.000 title claims description 6
238000004519 manufacturing process Methods 0.000 title description 3
150000003839 salts Chemical class 0.000 claims abstract description 14
239000004480 active ingredient Substances 0.000 claims abstract description 9
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 7
229940079593 drug Drugs 0.000 claims description 14
150000003214 pyranose derivatives Chemical class 0.000 claims description 8
SHZGCJCMOBCMKK-DVKNGEFBSA-N alpha-D-quinovopyranose Chemical group C[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O SHZGCJCMOBCMKK-DVKNGEFBSA-N 0.000 claims description 5
238000002360 preparation method Methods 0.000 claims description 5
235000014113 dietary fatty acids Nutrition 0.000 abstract description 26
239000000194 fatty acid Substances 0.000 abstract description 26
229930195729 fatty acid Natural products 0.000 abstract description 26
150000004665 fatty acids Chemical class 0.000 abstract description 25
125000002252 acyl group Chemical group 0.000 abstract description 23
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 39
238000006243 chemical reaction Methods 0.000 description 37
239000000243 solution Substances 0.000 description 31
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
229910052799 carbon Inorganic materials 0.000 description 23
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 21
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 19
210000004027 cell Anatomy 0.000 description 18
239000000203 mixture Substances 0.000 description 18
125000000217 alkyl group Chemical group 0.000 description 17
125000002887 hydroxy group Chemical group [H]O* 0.000 description 17
230000001093 anti-cancer Effects 0.000 description 16
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
125000004432 carbon atom Chemical group C* 0.000 description 14
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 14
-1 carbonylthio group Chemical group 0.000 description 13
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 13
238000011084 recovery Methods 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
238000004587 chromatography analysis Methods 0.000 description 11
125000006239 protecting group Chemical group 0.000 description 11
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
241000699670 Mus sp. Species 0.000 description 10
125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 10
238000003756 stirring Methods 0.000 description 10
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
238000004458 analytical method Methods 0.000 description 9
238000000034 method Methods 0.000 description 9
239000003960 organic solvent Substances 0.000 description 9
239000011541 reaction mixture Substances 0.000 description 9
239000000741 silica gel Substances 0.000 description 9
229910002027 silica gel Inorganic materials 0.000 description 9
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 8
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 8
239000012267 brine Substances 0.000 description 8
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 7
229960000583 acetic acid Drugs 0.000 description 7
125000004390 alkyl sulfonyl group Chemical group 0.000 description 7
150000002148 esters Chemical class 0.000 description 7
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 7
OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 6
YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 6
HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 6
150000005690 diesters Chemical class 0.000 description 6
238000002513 implantation Methods 0.000 description 6
230000002401 inhibitory effect Effects 0.000 description 6
SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 6
230000035484 reaction time Effects 0.000 description 6
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
125000003118 aryl group Chemical group 0.000 description 5
125000004391 aryl sulfonyl group Chemical group 0.000 description 5
239000003054 catalyst Substances 0.000 description 5
230000000694 effects Effects 0.000 description 5
239000007924 injection Substances 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007788 liquid Substances 0.000 description 5
239000012044 organic layer Substances 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
208000005718 Stomach Neoplasms Diseases 0.000 description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
238000003556 assay Methods 0.000 description 4
239000012153 distilled water Substances 0.000 description 4
206010017758 gastric cancer Diseases 0.000 description 4
229910000489 osmium tetroxide Inorganic materials 0.000 description 4
239000007800 oxidant agent Substances 0.000 description 4
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
201000011549 stomach cancer Diseases 0.000 description 4
125000001424 substituent group Chemical group 0.000 description 4
125000000547 substituted alkyl group Chemical group 0.000 description 4
150000003566 thiocarboxylic acids Chemical class 0.000 description 4
125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 4
235000021122 unsaturated fatty acids Nutrition 0.000 description 4
150000004670 unsaturated fatty acids Chemical class 0.000 description 4
JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 4
XJNKZTHFPGIJNS-ZEBDFXRSSA-N (2r,3s,4s,5r,6s)-2-(hydroxymethyl)-6-prop-2-enoxyoxane-3,4,5-triol Chemical compound OC[C@H]1O[C@H](OCC=C)[C@H](O)[C@@H](O)[C@@H]1O XJNKZTHFPGIJNS-ZEBDFXRSSA-N 0.000 description 3
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 3
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 3
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 3
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
206010009944 Colon cancer Diseases 0.000 description 3
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
241000725303 Human immunodeficiency virus Species 0.000 description 3
SHZGCJCMOBCMKK-PQMKYFCFSA-N L-Fucose Natural products C[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O SHZGCJCMOBCMKK-PQMKYFCFSA-N 0.000 description 3
239000005642 Oleic acid Substances 0.000 description 3
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
FYFMWZVCWPQWTA-SAEUYMBFSA-N [(2r,3r,4s,5r,6s)-3,4,5-tris[[tert-butyl(dimethyl)silyl]oxy]-6-prop-2-enoxyoxan-2-yl]methyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OC[C@@H]1[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O[Si](C)(C)C(C)(C)C)[C@@H](O[Si](C)(C)C(C)(C)C)[C@@H](OCC=C)O1 FYFMWZVCWPQWTA-SAEUYMBFSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000037396 body weight Effects 0.000 description 3
244000309466 calf Species 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
239000000460 chlorine Substances 0.000 description 3
208000029742 colonic neoplasm Diseases 0.000 description 3
229940126214 compound 3 Drugs 0.000 description 3
125000005843 halogen group Chemical group 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 3
239000002609 medium Substances 0.000 description 3
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
235000011056 potassium acetate Nutrition 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
150000008054 sulfonate salts Chemical class 0.000 description 3
239000000725 suspension Substances 0.000 description 3
ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 3
YWWVWXASSLXJHU-AATRIKPKSA-N (9E)-tetradecenoic acid Chemical compound CCCC\C=C\CCCCCCCC(O)=O YWWVWXASSLXJHU-AATRIKPKSA-N 0.000 description 2
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical class CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
JYWKEVKEKOTYEX-UHFFFAOYSA-N 2,6-dibromo-4-chloroiminocyclohexa-2,5-dien-1-one Chemical compound ClN=C1C=C(Br)C(=O)C(Br)=C1 JYWKEVKEKOTYEX-UHFFFAOYSA-N 0.000 description 2
XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
102000004594 DNA Polymerase I Human genes 0.000 description 2
108010017826 DNA Polymerase I Proteins 0.000 description 2
102000004214 DNA polymerase A Human genes 0.000 description 2
108090000725 DNA polymerase A Proteins 0.000 description 2
241000196324 Embryophyta Species 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
102100034343 Integrase Human genes 0.000 description 2
208000005016 Intestinal Neoplasms Diseases 0.000 description 2
206010058467 Lung neoplasm malignant Diseases 0.000 description 2
ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 2
ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
WLLIXJBWWFGEHT-UHFFFAOYSA-N [tert-butyl(dimethyl)silyl] trifluoromethanesulfonate Chemical compound CC(C)(C)[Si](C)(C)OS(=O)(=O)C(F)(F)F WLLIXJBWWFGEHT-UHFFFAOYSA-N 0.000 description 2
239000000654 additive Substances 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
229910052783 alkali metal Inorganic materials 0.000 description 2
229910052784 alkaline earth metal Inorganic materials 0.000 description 2
125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 2
SHZGCJCMOBCMKK-PHYPRBDBSA-N alpha-D-fucose Chemical compound C[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O SHZGCJCMOBCMKK-PHYPRBDBSA-N 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
125000005279 aryl sulfonyloxy group Chemical group 0.000 description 2
125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
SHZGCJCMOBCMKK-FPRJBGLDSA-N beta-D-fucose Chemical compound C[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O SHZGCJCMOBCMKK-FPRJBGLDSA-N 0.000 description 2
SHZGCJCMOBCMKK-VFUOTHLCSA-N beta-D-quinovopyranose Chemical compound C[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O SHZGCJCMOBCMKK-VFUOTHLCSA-N 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
150000001721 carbon Chemical group 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000007795 chemical reaction product Substances 0.000 description 2
229940125898 compound 5 Drugs 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
150000002009 diols Chemical class 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
238000006911 enzymatic reaction Methods 0.000 description 2
230000032050 esterification Effects 0.000 description 2
238000005886 esterification reaction Methods 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
239000007789 gas Substances 0.000 description 2
239000012362 glacial acetic acid Substances 0.000 description 2
239000008187 granular material Substances 0.000 description 2
150000002430 hydrocarbons Chemical group 0.000 description 2
201000002313 intestinal cancer Diseases 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
201000005202 lung cancer Diseases 0.000 description 2
208000020816 lung neoplasm Diseases 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
229910052750 molybdenum Inorganic materials 0.000 description 2
239000011733 molybdenum Substances 0.000 description 2
PGFPZGKEDZGJQZ-UHFFFAOYSA-N n,n-dimethylmethanamine oxide;dihydrate Chemical compound O.O.C[N+](C)(C)[O-] PGFPZGKEDZGJQZ-UHFFFAOYSA-N 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000002335 preservative effect Effects 0.000 description 2
RYVMUASDIZQXAA-UHFFFAOYSA-N pyranoside Natural products O1C2(OCC(C)C(OC3C(C(O)C(O)C(CO)O3)O)C2)C(C)C(C2(CCC3C4(C)CC5O)C)C1CC2C3CC=C4CC5OC(C(C1O)O)OC(CO)C1OC(C1OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OCC(O)C(O)C1O RYVMUASDIZQXAA-UHFFFAOYSA-N 0.000 description 2
125000003132 pyranosyl group Chemical group 0.000 description 2
KOUKXHPPRFNWPP-UHFFFAOYSA-N pyrazine-2,5-dicarboxylic acid;hydrate Chemical compound O.OC(=O)C1=CN=C(C(O)=O)C=N1 KOUKXHPPRFNWPP-UHFFFAOYSA-N 0.000 description 2
238000010992 reflux Methods 0.000 description 2
150000004671 saturated fatty acids Chemical class 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
239000011734 sodium Substances 0.000 description 2
HQEZHPYAKIOFDX-MZRJWMBVSA-M sodium;[(2s,3s,4s,5r,6s)-3,4,5-trihydroxy-6-[2-hydroxy-3-[(z)-octadec-9-enoyl]oxypropoxy]oxan-2-yl]methanesulfonate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO[C@H]1O[C@H](CS([O-])(=O)=O)[C@@H](O)[C@H](O)[C@H]1O HQEZHPYAKIOFDX-MZRJWMBVSA-M 0.000 description 2
239000007921 spray Substances 0.000 description 2
125000003107 substituted aryl group Chemical group 0.000 description 2
229910052717 sulfur Inorganic materials 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
239000003826 tablet Substances 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
230000005740 tumor formation Effects 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
235000005074 zinc chloride Nutrition 0.000 description 2
239000011592 zinc chloride Substances 0.000 description 2
SHZGCJCMOBCMKK-RWOPYEJCSA-N (2r,3s,4s,5s,6r)-6-methyloxane-2,3,4,5-tetrol Chemical compound C[C@H]1O[C@@H](O)[C@@H](O)[C@@H](O)[C@@H]1O SHZGCJCMOBCMKK-RWOPYEJCSA-N 0.000 description 1
GIGRWGTZFONRKA-UHFFFAOYSA-N 1-(bromomethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CBr)C=C1 GIGRWGTZFONRKA-UHFFFAOYSA-N 0.000 description 1
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
HDECRAPHCDXMIJ-UHFFFAOYSA-N 2-methylbenzenesulfonyl chloride Chemical compound CC1=CC=CC=C1S(Cl)(=O)=O HDECRAPHCDXMIJ-UHFFFAOYSA-N 0.000 description 1
229960000549 4-dimethylaminophenol Drugs 0.000 description 1
YWWVWXASSLXJHU-UHFFFAOYSA-N 9E-tetradecenoic acid Natural products CCCCC=CCCCCCCCC(O)=O YWWVWXASSLXJHU-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
241000195493 Cryptophyta Species 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
125000003535 D-glucopyranosyl group Chemical group [H]OC([H])([H])[C@@]1([H])OC([H])(*)[C@]([H])(O[H])[C@@]([H])(O[H])[C@]1([H])O[H] 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
229940123014 DNA polymerase inhibitor Drugs 0.000 description 1
241000257465 Echinoidea Species 0.000 description 1
PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
241001467355 Gigartina Species 0.000 description 1
208000032612 Glial tumor Diseases 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
229930186217 Glycolipid Natural products 0.000 description 1
SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
238000000134 MTT assay Methods 0.000 description 1
231100000002 MTT assay Toxicity 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
239000012359 Methanesulfonyl chloride Substances 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
235000021319 Palmitoleic acid Nutrition 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
LWAAMNZZPGQJKS-LJIZCISZSA-N [(2r,3s,4s,5r,6s)-3,4,5-trihydroxy-6-prop-2-enoxyoxan-2-yl]methyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OCC=C)O1 LWAAMNZZPGQJKS-LJIZCISZSA-N 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
239000003377 acid catalyst Substances 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
208000009956 adenocarcinoma Diseases 0.000 description 1
230000002411 adverse Effects 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
150000001338 aliphatic hydrocarbons Chemical group 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
230000036436 anti-hiv Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
UIJGNTRUPZPVNG-UHFFFAOYSA-N benzenecarbothioic s-acid Chemical compound SC(=O)C1=CC=CC=C1 UIJGNTRUPZPVNG-UHFFFAOYSA-N 0.000 description 1
CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
229940125782 compound 2 Drugs 0.000 description 1
239000013078 crystal Substances 0.000 description 1
UMNKXPULIDJLSU-UHFFFAOYSA-N dichlorofluoromethane Chemical compound FC(Cl)Cl UMNKXPULIDJLSU-UHFFFAOYSA-N 0.000 description 1
229940099364 dichlorofluoromethane Drugs 0.000 description 1
238000005906 dihydroxylation reaction Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
208000010932 epithelial neoplasm Diseases 0.000 description 1
FRYHCSODNHYDPU-UHFFFAOYSA-N ethanesulfonyl chloride Chemical compound CCS(Cl)(=O)=O FRYHCSODNHYDPU-UHFFFAOYSA-N 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
238000003818 flash chromatography Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000008101 lactose Substances 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
238000002156 mixing Methods 0.000 description 1
PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
238000011580 nude mouse model Methods 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
238000012335 pathological evaluation Methods 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
229910000343 potassium bisulfate Inorganic materials 0.000 description 1
229910001414 potassium ion Inorganic materials 0.000 description 1
229910052939 potassium sulfate Inorganic materials 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000000047 product Substances 0.000 description 1
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
239000001294 propane Substances 0.000 description 1
KOODSCBKXPPKHE-UHFFFAOYSA-N propanethioic s-acid Chemical compound CCC(S)=O KOODSCBKXPPKHE-UHFFFAOYSA-N 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910001415 sodium ion Inorganic materials 0.000 description 1
MRIHMSOATDNRSH-WVXKJOBZSA-M sodium;[(2s,3r,4s,5r,6s)-3,4,5-tris[[tert-butyl(dimethyl)silyl]oxy]-6-[2-hydroxy-3-[(z)-octadec-9-enoyl]oxypropoxy]oxan-2-yl]methanesulfonate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO[C@H]1O[C@H](CS([O-])(=O)=O)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]1O[Si](C)(C)C(C)(C)C MRIHMSOATDNRSH-WVXKJOBZSA-M 0.000 description 1
ZQNNTXKYHSTOIJ-FYERSGSWSA-M sodium;[(2s,3s,4s,5r,6s)-6-[3-[(z)-hexadec-9-enoyl]oxy-2-hydroxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonate Chemical compound [Na+].CCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO[C@H]1O[C@H](CS([O-])(=O)=O)[C@@H](O)[C@H](O)[C@H]1O ZQNNTXKYHSTOIJ-FYERSGSWSA-M 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000008227 sterile water for injection Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
125000005480 straight-chain fatty acid group Chemical group 0.000 description 1
239000000126 substance Substances 0.000 description 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
125000004434 sulfur atom Chemical group 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 1
BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
150000004685 tetrahydrates Chemical class 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
238000004448 titration Methods 0.000 description 1
UYPYRKYUKCHHIB-UHFFFAOYSA-N trimethylamine N-oxide Chemical compound C[N+](C)(C)[O-] UYPYRKYUKCHHIB-UHFFFAOYSA-N 0.000 description 1
JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 1
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
229930195735 unsaturated hydrocarbon Chemical group 0.000 description 1
230000002792 vascular Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
- C07H15/06—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical being a hydroxyalkyl group esterified by a fatty acid

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Biotechnology (AREA)
Crystallography & Structural Chemistry (AREA)
Biochemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Genetics & Genomics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Seasonings (AREA)

NO20014119A 1999-02-26 2001-08-24 Farmasoytisk preparat inneholdende et sulfopyranosylacylglyserolderivat, slike forbindelser for anvendelse ved behandling av kreft, samt anvendelse av forbindelsene ved fremstilling av medikamenter NO329209B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP5139799		1999-02-26
PCT/JP2000/000973 WO2000051622A1 (fr)	1999-02-26	2000-02-21	Medicaments contenant des derives du sulfopyranosylacylglycerol

Publications (3)

Publication Number	Publication Date
NO20014119D0 NO20014119D0 (no)	2001-08-24
NO20014119L NO20014119L (no)	2001-10-24
NO329209B1 true NO329209B1 (no)	2010-09-13

Family

ID=12885820

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20014119A NO329209B1 (no)	1999-02-26	2001-08-24	Farmasoytisk preparat inneholdende et sulfopyranosylacylglyserolderivat, slike forbindelser for anvendelse ved behandling av kreft, samt anvendelse av forbindelsene ved fremstilling av medikamenter

Country Status (13)

Country	Link
US (3)	US6770629B2 (pt)
EP (1)	EP1172107B1 (pt)
JP (1)	JP3771445B2 (pt)
KR (1)	KR100528874B1 (pt)
CN (1)	CN1151795C (pt)
AT (1)	ATE348623T1 (pt)
AU (1)	AU764246B2 (pt)
BR (1)	BR0008516A (pt)
CA (1)	CA2365359C (pt)
DE (1)	DE60032470T2 (pt)
EA (1)	EA003094B1 (pt)
NO (1)	NO329209B1 (pt)
WO (1)	WO2000051622A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3851461B2 (ja)	1998-09-04	2006-11-29	東洋水産株式会社	ピラノシドおよびその製造方法
BR0008516A (pt) *	1999-02-26	2001-11-06	Toyo Suisan Kaisha	Medicamento contendo um derivado sulfo piranosil acil glicerol
CA2362903C (en)	1999-02-26	2006-06-13	Toyo Suisan Kaisha, Ltd.	Novel sulfofucosylacylglycerol derivatives and use thereof as medicaments
EP1405640B1 (en) *	2001-07-09	2009-03-25	Toyo Suisan Kaisha, Ltd.	Novel immunosuppressants
FR2840318B1 (fr) *	2002-05-29	2004-12-03	Quoc Kiet Pham	Nouveaux sulfolipides antiretroviraux extraits de spirulines, leur procede d'obtention, les compositions les contenant et leur utilisation comme inhibiteurs de la transcriptase inverse des virus vih
NO20025738D0 (no) *	2002-11-29	2002-11-29	Amersham Health As	Metode
KR100733028B1 (ko) *	2003-08-29	2007-06-28	사토 세이야쿠 가부시키가이샤	직장 투여용 제제
US20070219145A1 (en)	2004-06-24	2007-09-20	Ippei Sakimoto	Radiosensitizer
AU2008278337B2 (en) *	2007-07-20	2011-09-29	Toyo Suisan Kaisha, Ltd.	Novel sulfonated sugar compound and use thereof as medicine
EA201170819A1 (ru) *	2009-01-16	2012-04-30	Тойо Суйсан Кайся, Лтд.	Соединение, обладающее свойством удерживания в опухоли
JP2013519706A (ja)	2010-02-18	2013-05-30	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	癌転移を予防するための方法
US10842494B2 (en)	2011-10-17	2020-11-24	University Of Utah Research Foundation	Methods and devices for connecting nerves
EP2768425B1 (en)	2011-10-17	2018-11-14	University of Utah Research Foundation	Methods and devices for connecting nerves
DE102015011780A1 (de) *	2015-09-16	2017-03-16	Hochschule Anhalt	Neue Glutaminylcyclase-lnhibitoren
JP6903273B1 (ja)	2020-09-25	2021-07-14	株式会社エム・ティー・スリー	化合物又はその塩、及び放射性増感剤
CN113476610A (zh) *	2021-08-13	2021-10-08	云南中医药大学	甘油衍生物与抗真菌药物组成的抗真菌药物组合物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS55130996A (en) *	1979-03-30	1980-10-11	Rikagaku Kenkyusho	Novel maltose derivative and its preparation
JPS6040159A (ja) *	1983-08-15	1985-03-02	Nissan Motor Co Ltd	強化形防錆ワツクス
JP2872695B2 (ja) *	1989-07-19	1999-03-17	エーザイ株式会社	腎炎の治療剤
JP2872694B2 (ja) *	1989-07-19	1999-03-17	エーザイ株式会社	血管内血液凝固症候群の治療剤
JPH0366603A (ja) *	1989-08-04	1991-03-22	Mikio Nakanishi	界面活性剤を用いる赤潮プランクトンの駆除方法
EP0486536B1 (en) *	1989-08-15	1994-10-26	THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce	Antiviral compositions containing sulfoquinovosyl glycerol derivatives and analogs thereof
JPH03246203A (ja) *	1990-02-20	1991-11-01	Mikio Nakanishi	赤潮プランクトンの駆除方法
US5695752A (en) *	1992-09-11	1997-12-09	The Regents Of The University Of California	Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
US5783693A (en) *	1993-11-19	1998-07-21	The Regents Of The University Of California	Methods for synthesizing sulfated disaccharide inhibitors of selectins
WO1995013819A1 (en) *	1993-11-19	1995-05-26	The Regents Of The University Of California	Sulfated ligands for l-selectin and methods of preventing sulfate addition
JPH07149786A (ja)	1993-11-26	1995-06-13	Sagami Chem Res Center	グリセロ糖脂質及び発癌プロモーター阻害剤
JPH07242691A (ja)	1994-01-17	1995-09-19	Sankyo Co Ltd	１位にカルボキシメチレン基を有する４−ホスホノグルコサミン類
JPH09268198A (ja)	1996-04-02	1997-10-14	Sanei Touka Kk	ＤＮＡポリメラーゼα阻害物質及びその製造方法
SE9601677D0 (sv) *	1996-05-02	1996-05-02	Scotia Lipidteknik Ab	New use
JP4454051B2 (ja) *	1997-01-24	2010-04-21	東洋水産株式会社	新規な糖脂質、その製造方法及びその用途
JP3851461B2 (ja) *	1998-09-04	2006-11-29	東洋水産株式会社	ピラノシドおよびその製造方法
CA2362903C (en)	1999-02-26	2006-06-13	Toyo Suisan Kaisha, Ltd.	Novel sulfofucosylacylglycerol derivatives and use thereof as medicaments
BR0008516A (pt) *	1999-02-26	2001-11-06	Toyo Suisan Kaisha	Medicamento contendo um derivado sulfo piranosil acil glicerol
EP1164139B1 (en)	1999-02-26	2003-07-09	Toyo Suisan Kaisha, Ltd.	Novel sulforhamnosylacylglycerol derivatives and use thereof as medicaments
US6518410B2 (en) *	1999-02-26	2003-02-11	Toyo Suisan Kaisha, Ltd.	Sulfoquinovosylacylglycerol derivative, and use thereof as medicaments
AU765950B2 (en)	1999-03-11	2003-10-02	Toyo Suisan Kaisha, Ltd.	Novel immunosuppressants

2000
- 2000-02-21 BR BR0008516-2A patent/BR0008516A/pt not_active Application Discontinuation
- 2000-02-21 CN CNB008043027A patent/CN1151795C/zh not_active Expired - Fee Related
- 2000-02-21 EA EA200100916A patent/EA003094B1/ru not_active IP Right Cessation
- 2000-02-21 AU AU25755/00A patent/AU764246B2/en not_active Ceased
- 2000-02-21 KR KR10-2001-7010750A patent/KR100528874B1/ko not_active IP Right Cessation
- 2000-02-21 EP EP00904069A patent/EP1172107B1/en not_active Expired - Lifetime
- 2000-02-21 CA CA002365359A patent/CA2365359C/en not_active Expired - Fee Related
- 2000-02-21 WO PCT/JP2000/000973 patent/WO2000051622A1/ja active IP Right Grant
- 2000-02-21 DE DE60032470T patent/DE60032470T2/de not_active Expired - Lifetime
- 2000-02-21 AT AT00904069T patent/ATE348623T1/de not_active IP Right Cessation
- 2000-02-21 JP JP2000602289A patent/JP3771445B2/ja not_active Expired - Fee Related
2001
- 2001-08-22 US US09/934,874 patent/US6770629B2/en not_active Expired - Fee Related
- 2001-08-24 NO NO20014119A patent/NO329209B1/no not_active IP Right Cessation
2003
- 2003-10-02 US US10/678,193 patent/US7148200B2/en not_active Expired - Fee Related
2006
- 2006-07-03 US US11/480,657 patent/US7378398B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP1172107A1 (en)	2002-01-16
US7148200B2 (en)	2006-12-12
US7378398B2 (en)	2008-05-27
CN1341025A (zh)	2002-03-20
AU2575500A (en)	2000-09-21
NO20014119L (no)	2001-10-24
US20060252703A1 (en)	2006-11-09
CA2365359C (en)	2007-09-18
WO2000051622A1 (fr)	2000-09-08
BR0008516A (pt)	2001-11-06
EA003094B1 (ru)	2002-12-26
DE60032470T2 (de)	2007-10-11
AU764246B2 (en)	2003-08-14
JP3771445B2 (ja)	2006-04-26
US20020028776A1 (en)	2002-03-07
DE60032470D1 (de)	2007-02-01
EP1172107B1 (en)	2006-12-20
EP1172107A4 (en)	2003-07-23
US20040067893A1 (en)	2004-04-08
EA200100916A1 (ru)	2002-02-28
NO20014119D0 (no)	2001-08-24
US6770629B2 (en)	2004-08-03
ATE348623T1 (de)	2007-01-15
KR20010114211A (ko)	2001-12-31
KR100528874B1 (ko)	2005-11-15
CA2365359A1 (en)	2000-09-08
CN1151795C (zh)	2004-06-02

Publication	Publication Date	Title
US7378398B2 (en)	2008-05-27	Method for treating cancer
US6518248B1 (en)	2003-02-11	Method of treating gastric or colon cancer by administration of a sulfoquinovosylacylglycerol ester
EP1164139B1 (en)	2003-07-09	Novel sulforhamnosylacylglycerol derivatives and use thereof as medicaments
US6518410B2 (en)	2003-02-11	Sulfoquinovosylacylglycerol derivative, and use thereof as medicaments
EP1172108B1 (en)	2004-12-22	Use of Sulfoquinovosyldiacylglycerol derivatives as immunosuppressants
EP1164140B1 (en)	2003-07-09	Novel sulfofucosylacylglycerol derivatives and utilization thereof as drugs
EP1405640B1 (en)	2009-03-25	Novel immunosuppressants

Legal Events

Date	Code	Title	Description
2013-09-30	MM1K	Lapsed by not paying the annual fees